'Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trials'

Credit: IndiaTimes- Published on June 22, 2021
Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee of the Indian drug regulator. The panel has approved the trial data which is based on 25,800 subjects. Covaxin is one of the three...

Video credit: Oneindia
Published on June 22, 2021 -  02:03
Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News
Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 according to data from Phase III trials conducted on 25,800 participants across India. The data was submitted to the DCGI over the weekend. #BharatBiotech #Covaxin #Covid19

You are here


๐Ÿ’ก newsR Knowledge: Other News Mentions

Covaxin

Vaccine against COVID-19
An expert panel of India's central drug authority on Thursday recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a..
Credit: IndiaTimes - Published 23 hours ago

After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotechโ€™s Covaxin, Brazilโ€™s health regulator Anvisa..
Credit: IndiaTimes - Published 2 days ago

After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazilโ€™s..
Credit: IndiaTimes - Published 3 days ago

In view of a probable third wave of the pandemic, vaccination trials on children have been underway in India with Covaxin and Zydus Cadila's ZyCov-D.
Credit: DNA - Published 6 days ago


Bharat Biotech

Indian biotechnology company and vaccine manufacturer
Credit: IndiaTimes - Published 3 days ago

Bharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation..
Credit: IndiaTimes - Published 1 week ago



COVID-19

Disease caused by severe acute respiratory syndrome coronavirus 2
Easing of lockdown combined with pandemic fatigue, lack of community adherence to Covid-appropriate behavior, and circulation of more transmissible variants of..
Credit: IndiaTimes - Published 4 hours ago

The team treated various coins, banknotes with virus solutions of different concentrations and observed how long infectious virus was detectable.
Credit: DNA - Published 5 hours ago


Related videos from verified sources

Covaxin approval: WHO chief scientist says Phase-3 data looks promising| Covid-19| Oneindia News 02:46
Credit: Oneindia - Published 3 weeks ago 


Covaxin is 77.8% effective against Covid-19, claims Bharat Biotech: Details | Oneindia News 02:13
Credit: Oneindia - Published on July 3, 2021 


Covaxin neutralizes both Alpha & Delta variants of coronavirus: US Institute| Oneindia News 02:11
Credit: Oneindia - Published on June 30, 2021 


Related news from verified sources

Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the...
on June 22, 2021 • IndiaTimes

Bharat Biotech is going to conduct a phase 4 trial of its COVID-19 vaccine, Covaxin, in order to check the real-world effectiveness. The company revealed that...
on June 10, 2021 • Zee News

You might like